2259 related articles for article (PubMed ID: 23683734)
1. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
[TBL] [Abstract][Full Text] [Related]
2. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
3. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
4. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
5. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial.
Kaltoft A; Kelbaek H; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
J Am Coll Cardiol; 2010 Aug; 56(8):641-5. PubMed ID: 20688033
[TBL] [Abstract][Full Text] [Related]
7. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
[TBL] [Abstract][Full Text] [Related]
9. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
10. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
11. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction.
Wijnbergen I; Tijssen J; Brueren G; Peels K; van Dantzig JM; Veer MV; Koolen JJ; Michels R; Pijls NH
Coron Artery Dis; 2014 Aug; 25(5):378-83. PubMed ID: 24736301
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
[TBL] [Abstract][Full Text] [Related]
13. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
14. New generation drug-eluting stents for ST-elevation myocardial infarction: a new paradigm for safety.
Garg A; Brodie BR; Stuckey TD; Garberich RF; Tobbia P; Hansen C; Kissling G; Kadakia H; Lips D; Henry TD
Catheter Cardiovasc Interv; 2014 Nov; 84(6):955-62. PubMed ID: 24174334
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction.
Wijnbergen I; Tijssen J; van 't Veer M; Michels R; Pijls NH
Catheter Cardiovasc Interv; 2013 Sep; 82(3):379-84. PubMed ID: 23553888
[TBL] [Abstract][Full Text] [Related]
16. Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry.
Siudak Z; Dziewierz A; Rakowski T; Żmudka K; Legutko J; Bartuś S; Dragan J; Zasada W; Tokarek T; Kułaga T; Partyka Ł; Dudek D
Catheter Cardiovasc Interv; 2014 Feb; 83(3):436-42. PubMed ID: 24038740
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
Jiménez-Quevedo P; Hernando L; Gómez-Hospital JA; Iñiguez A; SanRoman A; Alfonso F; Hernández-Antolín R; Angiolillo DJ; Bañuelos C; Escaned J; Gonzalo N; Fernández C; Macaya C; Sabaté M;
EuroIntervention; 2013 Jul; 9(3):328-35. PubMed ID: 23518240
[TBL] [Abstract][Full Text] [Related]
18. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
20. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]